Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · IEX Real-Time Price · USD
6.26
+0.10 (1.62%)
At close: May 3, 2024, 4:00 PM
6.47
+0.21 (3.35%)
After-hours: May 3, 2024, 5:30 PM EDT
Travere Therapeutics Revenue
In the year 2023, Travere Therapeutics had annual revenue of $145.24M with 32.69% growth. Revenue in the quarter ending December 31, 2023 was $45.06M with 53.58% year-over-year growth.
Revenue (ttm)
$145.24M
Revenue Growth
+32.69%
P/S Ratio
3.28
Revenue / Employee
$382,205
Employees
380
Market Cap
476.38M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
Dec 31, 2014 | 28.20M | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Community Health Systems | 12.52B |
Voyager Therapeutics | 250.01M |
Surmodics | 142.96M |
Editas Medicine | 78.12M |
Fate Therapeutics | 63.53M |
Fulcrum Therapeutics | 2.81M |
Oculis Holding AG | 1.05M |
TVTX News
- 5 days ago - Travere Therapeutics to Report First Quarter 2024 Financial Results - GlobeNewsWire
- 10 days ago - Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - GlobeNewsWire
- 10 days ago - CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PRNewsWire
- 4 weeks ago - Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International - GlobeNewsWire
- 4 weeks ago - Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association - GlobeNewsWire
- 7 weeks ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire